Assessing the Heterogeneity of Response of [68Ga] Ga-PSMA-11 PET/CT Lesions in Patients With Biochemical Recurrence of Prostate Cancer

被引:0
|
作者
Dell'Oro, Mikaela [1 ]
Huff, Daniel T. [2 ]
Lokre, Ojaswita [2 ]
Kendrick, Jake [3 ,4 ]
Govindan, Rajkumar Munian [2 ]
Ong, Jeremy S. L. [5 ]
Ebert, Martin A. [1 ,3 ,4 ,6 ]
Perk, Timothy G. [2 ]
Francis, Roslyn J. [1 ,7 ]
机构
[1] Univ Western Australia, Australian Ctr Quantitat Imaging, Sch Med, Level 5,Harry Perkins,5 Verdun St, Perth, 6009, Australia
[2] AIQ Solut, Madison, WI USA
[3] Univ Western Australia, Sch Phys Math & Comp, Perth, Australia
[4] Ctr Adv Technol Canc Res, Perth, Australia
[5] Fiona Stanley Hosp, Dept Nucl Med, Murdoch, Australia
[6] Sir Charles Gairdner Hosp, Dept Radiat Oncol, Nedlands, Australia
[7] Sir Charles Gairdner Hosp, Dept Nucl Med, Nedlands, Australia
基金
美国国家卫生研究院;
关键词
Metastatic prostate cancer; PSMA PET/CT; Image features; Response heterogeneity; CRITERIA; THERAPY; RECIST; PERCIST; PSMA;
D O I
10.1016/j.clgc.2024.102155
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In this study, special imaging called PSMA PET/CT was analyzed for 199 men with advanced prostate cancer. Computer software was used to monitor each tumor over 6-months. The research found that 25% of men had tumors that responded differently, which was linked to shorter overall survival. Recognizing these patients early could help doctors monitor them closely and provide treatment sooner. Introduction: Treatment of men with metastatic prostate cancer can be difficult due to the heterogeneity of response of lesions. [(68) Ga]Ga-PSMA-11 (PSMA) PET/CT assists with monitoring and directing clinical intervention; however, the impact of response heterogeneity has yet to be related to outcome measures. The aim of this study was to assess the impact of quantitative imaging information on the value of PSMA PET/CT to assess patient outcomes in response evaluation. Patients and Methods: Baseline and follow-up (6 months) PSMA PET/CT of 162 men with oligometastatic PC treated with standard clinical care were acquired between 2015 and 2016 for analysis. An augmentative software medical device was used to track lesions between scans and quantify lesion change to categorize them as either new, increasing, stable, decreasing, or disappeared. Quantitative imaging features describing the size, intensity, extent, change, and heterogeneity of change (based on percent change in SUVtotal ) among lesions were extracted and evaluated for association with overall survival (OS) using Cox regression models .Model performance was evaluated using the c-index. Results: Forty-one (25%) of subjects demonstrated heterogeneous response at follow-up, defined as having at least 1 new or increasing lesion and at least 1 decreasing or disappeared lesion. Subjects with heterogeneous response demonstrated significantly shorter OS than subjects without (median OS = 76.6 months vs. median OS not reached, P < .05, c-index = 0.61). In univariate analyses, SUVtotal at follow-up was most strongly associated with OS (HR = 1.29 [1.19, 1.40], P < .001, c-index = 0.73). Multivariable models applied using heterogeneity of change features demonstrated higher performance (c-index = 0.79) than models without (c-index = 0.71-0.76, P < .05). Conclusion: Augmentative software tools enhance the evaluation change on serial PSMA PET scans and can facilitate lesional evaluation between timepoints. This study demonstrates that a heterogeneous response at a lesional level may impact adversely on patient outcomes and suppor ts fur ther investigation to evaluate the role of imaging to guide individualized patient management to improve clinical outcomes.
引用
下载
收藏
页数:12
相关论文
共 50 条
  • [1] [68Ga]Ga-PSMA-11 PET-CT: Local preliminary experience in prostate cancer biochemical recurrence patients
    Carvalho, Joao
    Nunes, Pedro
    Da Silva, Edgar Tavares
    Silva, Rodolfo
    Lima, Joao
    Quaresma, Vasco
    Figueiredo, Arnaldo
    ARCHIVIO ITALIANO DI UROLOGIA E ANDROLOGIA, 2021, 93 (01) : 21 - 25
  • [2] Outcomes of [68Ga]Ga-PSMA-11 PET/CT in biochemical recurrence after brachytherapy
    Prospero, I.
    Ferreira, G.
    Ferro, J. C.
    Barbosa, D.
    Silva, D. G.
    Leite Silva, P.
    Fontao de Castro, S.
    Teixeira, J. P.
    Duarte, H.
    Lucena Sampaio, I.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S528 - S529
  • [3] [68Ga]Ga-PSMA-11 PET/CT in patients with recurrence of prostate cancer - usefulness of delayed phase in pelvic lesions detection
    Krolicki, L.
    Pelka, K.
    Kujda, S.
    Kunikowska, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S364 - S364
  • [4] Assessing dynamic metabolic heterogeneity in prostate cancer patients via total-body [68Ga]Ga-PSMA-11 PET/CT imaging: quantitative analysis of [68Ga]Ga-PSMA-11 uptake in pathological lesions and normal organs
    Ruohua Chen
    Yee Ling Ng
    Xinlan Yang
    Yinjie Zhu
    Lianghua Li
    Haitao Zhao
    Gang Huang
    Jianjun Liu
    European Journal of Nuclear Medicine and Molecular Imaging, 2024, 51 : 896 - 906
  • [5] Assessing dynamic metabolic heterogeneity in prostate cancer patients via total-body [68Ga]Ga-PSMA-11 PET/CT imaging: quantitative analysis of [68Ga]Ga-PSMA-11 uptake in pathological lesions and normal organs
    Chen, Ruohua
    Ng, Yee Ling
    Yang, Xinlan
    Zhu, Yinjie
    Li, Lianghua
    Zhao, Haitao
    Huang, Gang
    Liu, Jianjun
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 (03) : 896 - 906
  • [6] Pattern of prostate cancer recurrence in patients with biochemical failure following definitive therapy evaluated with [68Ga]Ga-PSMA-11 PET/CT
    Lawal, I.
    Lengana, T.
    Mokoala, K.
    Boshomane, T.
    Kleynhans, J.
    Vorster, M.
    Mokgoro, N.
    Sathekge, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S363 - S364
  • [7] The impact of (68Ga)-Ga-PSMA-11 PET/CT in primary staging of prostate cancer
    Weitzer, F.
    Pernthaler, B.
    Plhak, E.
    Riedl, R.
    Aigner, R. M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S458 - S458
  • [8] 68Ga PSMA PET/CT in Restaging of Prostate Cancer Patients with Biochemical Recurrence
    Seniaray, Nikhil
    Verma, Ritu
    Khanna, Sudhir
    Pruthi, Ankur
    Belho, Ethel
    Mahajan, Harsh
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [9] Systemic therapy response evaluation in prostate carcinoma with [68Ga]Ga-PSMA-11 PET/CT
    Kadir Alper Kucuker
    Zeynep Yapar
    Isa Burak Guney
    Semra Paydas
    Egyptian Journal of Radiology and Nuclear Medicine, 53
  • [10] Systemic therapy response evaluation in prostate carcinoma with [68Ga]Ga-PSMA-11 PET/CT
    Kucuker, Kadir Alper
    Yapar, Zeynep
    Guney, Isa Burak
    Paydas, Semra
    EGYPTIAN JOURNAL OF RADIOLOGY AND NUCLEAR MEDICINE, 2022, 53 (01):